Qureator provides a high‑throughput microphysiological system called Curiochips that recreates 3D human tissue architectures, including vascularized tumor‑immune microenvironments and organoids derived from patient samples. Integrated AI (QuriCore) analyzes image and biochemical data to predict efficacy, dosage, and biomarker responses, enabling target identification, combination screening, and patient stratification for pharma, biotech, and academic researchers.
Funding
$9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Preclinical drug discovery often relies on animal models or simple cell cultures that fail to accurately predict human responses, leading to high failure rates, costly late‑stage attrition, and delayed access to effective therapies for complex diseases.
Solution
Qureator addresses this gap with its proprietary Curiochips platform, a high‑throughput microphysiological system (HT‑MPS) that recreates human tissue architecture in 3D organ‑on‑chip formats. The open‑channel chips support vascularized tumor‑immune microenvironments, organoid cultures, and multi‑cellular constructs derived from primary patient samples, enabling physiologically relevant testing of small molecules, biologics, cell and gene therapies, and CRISPR interventions. Integrated AI (QuriCore) extracts image and biochemical features, applies graph neural networks, and predicts efficacy, dosage, and biomarker responses across diverse disease models such as cancer metastasis, immuno‑oncology, AMD, DILI, and BBB permeability. Researchers can use the platform for target identification, combination screening, and patient stratification, accelerating the translation of discoveries into clinical candidates while reducing reliance on animal studies.
Target Audience
Primary customers are pharmaceutical and biotech companies, as well as academic research groups, that require human‑relevant preclinical models for target discovery, lead optimization, and safety assessment across therapeutic areas such as oncology, ophthalmology, hepatology, and neuro‑vascular diseases.
Features
- Open‑channel Curiochips that support vascularized, multi‑cellular human tissue models, including tumor‑immune microenvironments and organoids
- High‑throughput screening capability for small molecules, biologics, cell/gene therapies, and CRISPRi within a single platform
- AI‑driven QuriCore engine employing graph neural networks for 3D image analysis, biochemical data integration, and predictive modeling of efficacy, dose response, and biomarkers
- Ability to incorporate patient‑derived primary cells and omics data for personalized disease modeling and patient stratification
- End‑to‑end workflow from tissue fabrication to data extraction, cloud‑based analytics, and actionable reports for target validation and combination therapy discovery